JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.23 CNY | -3.93% |
|
-0.62% | -60.54% |
Jiangsu gdk Biotechnology Co Ltd is a biopharmaceutical company engaged in the research, development, production, and sales of human vaccines. The Companyâs main product is a tetravalent influenza virus split vaccine, which is mainly used to prevent influenza caused by two influenza A virus strains and two influenza B virus strains. The Company's research products also include a variety of human vaccines for the prevention of epidemic colds, rabies, chickenpox, shingles, and pneumonia. The Company distributes its service within the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
11.23
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -60.54% | 191M | |
| +7.40% | 101B | |
| +7.76% | 42.18B | |
| -14.37% | 32.26B | |
| +81.37% | 29.79B | |
| -12.27% | 16.06B | |
| +2.33% | 14.45B | |
| -8.56% | 12.01B | |
| +182.74% | 10.71B | |
| +2.25% | 8.89B |
- Stock Market
- Equities
- 688670 Stock
- News Jiangsu Gdk Biological Technology Co., Ltd
- Jiangsu Gdk Biotechnology Forecasts Lower Profit in 2022 on COVID-19 Outbreaks
